PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast - James A. Underberg, MD, MS, FACPM, FACP, FNYAM, FASPC, FNLA - Management of Hyperlipidemia in the Family Medicine Setting: Diagnosis, Management, and the Role of Emerging Lipid-Lowering Therapies

James A. Underberg, MD, MS, FACPM, FACP, FNYAM, FASPC, FNLA - Management of Hyperlipidemia in the Family Medicine Setting: Diagnosis, Management, and the Role of Emerging Lipid-Lowering Therapies

06/28/21 • 53 min

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast

Go online to PeerView.com/UCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hyperlipidemia discusses best practices for the treatment of hyperlipidemia, including currently available and emerging investigational lipid-lowering therapies. Upon completion of this activity, participants should be better able to: Summarize the diagnostic evaluation and current clinical guidelines for the treatment of hyperlipidemia, Identify the mechanisms of action and safety-efficacy data of currently available and emerging investigational lipid-lowering therapies, Employ available clinical evidence to recognize patients who may benefit from emerging PCSK9-targeting therapies, Evaluate the role of multidisciplinary collaboration and patient education to optimize outcomes in patients with hyperlipidemia.

Previous Episode

undefined - Professor Kausik Ray - Lower Is Better: Novel Therapeutic Strategies Targeting PCSK9 for Reducing LDL-C Levels in Patients With Hyperlipidemia and ASCVD

Professor Kausik Ray - Lower Is Better: Novel Therapeutic Strategies Targeting PCSK9 for Reducing LDL-C Levels in Patients With Hyperlipidemia and ASCVD

Go online to PeerView.com/KXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hyperlipidemia discuss clinical evidence and guideline recommendations for the treatment of hyperlipidemia, for both primary and secondary prevention of CV events in patients with ASCVD. Upon completion of this activity, participants should be better able to: Summarize current clinical evidence and guideline recommendations for the treatment of hyperlipidemia, both for primary and secondary prevention of cardiovascular events in patients with ASCVD, Identify novel mechanisms of action and safety-efficacy evidence for approved and emerging investigational lipid-lowering therapies that target PCSK9, Select an appropriate lipid-lowering therapy including available and emerging agents, alone or in combination for providing guideline-directed LDL-C reduction and cardiovascular risk reduction in patients with high-risk ASCVD.

Next Episode

undefined - Christopher D. Still, DO, FACP, FTOS / Alan C. Wittgrove, MD, FASMBS, FACS - Going With Your Gut: Targeting Long-Term Weight Loss With Current and Emerging Incretin-Based Pharmacotherapy

Christopher D. Still, DO, FACP, FTOS / Alan C. Wittgrove, MD, FASMBS, FACS - Going With Your Gut: Targeting Long-Term Weight Loss With Current and Emerging Incretin-Based Pharmacotherapy

Go online to PeerView.com/FQJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, which is based on a recent live web broadcast, two obesity experts discuss weight-loss pharmacotherapy in the context of bariatric surgery as part of practical, case-centered sessions, designed to mimic the treatment considerations faced in real-world practice and illustrate how incretin-based agents can be used to individualize long-term obesity management and improve patient outcomes. Upon completion of this accredited CE activity, participants should be better able to: Recognize the roles of treatment options used adjunct to lifestyle interventions, particularly weight-loss pharmacotherapy and surgery, in addressing obesity pathophysiology, including metabolic adaptation, Assess the available evidence on current and emerging options in incretin-based weight-loss pharmacotherapies, including long-term efficacy and safety data, Integrate incretin-based pharmacotherapy into individualized, evidence-based treatment plans for long-term obesity management.